Phaseline

Targets › ATM

ATM (Serine-protein kinase ATM): drug programs, companies and trials

6 programs from 6 companies in 16 trials: 15 Phase 1, 1 Phase 2; Oncology, Neurology; next expected readout Dec 2026.

Serine/threonine protein kinase which activates checkpoint signaling upon double strand breaks (DSBs), apoptosis and genotoxic stresses such as ionizing ultraviolet A light (UVA), thereby acting as a DNA damage sensor. Recognizes the substrate consensus sequence [ST]-Q. Phosphorylates 'Ser-139' of histone variant H2AX at double strand breaks (DSBs), thereby regulating DNA damage response mechanism (By similarity). (UniProt, Q13315)

Open in Phaseline: the race on ATM, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
David Reardon, MDCC-115
mTOR and ATM kinase inhibitor
MTOR, ATMPhase 2GlioblastomaFeb 2028
National Cancer Institute (NCI)Peposertib
DNA-PKcs inhibitor
PRKDC, ATMPhase 1Advanced Head and Neck Squamous Cell Carcinoma; Neuroendocrine Neoplasm; Metastatic Castration-Resistant Prostate Carcinoma; Metastatic Dedifferentiated Liposarcoma …Dec 2026
ExelixisXL309 (ISM3091)
ATM inhibitor
ATMPhase 1Advanced Solid TumorApr 2027
Children's Oncology GroupAZD1390
ATM kinase inhibitor
ATMPhase 1Childhood AstrocytomaMar 2028
Timothy YuAtipeksen
Splice-switching antisense oligonucleotide targeting ATM c.7865C>T mutation to restore nor
ATMPhase 1Ataxia TelangiectasiaDec 2032
AstraZenecaAZD1390
ATM inhibitor
ATMPhase 1Recurrent Glioblastoma Multiforme; Non Small Cell Lung Cancer; Solid Tumor–

Conditions

Advanced Head and Neck Squamous Cell Carcinoma (1) Neuroendocrine Neoplasm (1) Metastatic Castration-Resistant Prostate Carcinoma (1) Metastatic Dedifferentiated Liposarcoma (1) Endometrial High Grade Endometrioid Adenocarcinoma (1) Recurrent Acute Myeloid Leukemia (1) Locally Advanced Malignant Solid Neoplasm (1) Locally Advanced Pancreatic Adenocarcinoma (1) Advanced Malignant Solid Neoplasm (1) Ataxia Telangiectasia (1) Childhood Astrocytoma (1) Glioblastoma (1)

Modalities

small molecule (3), mixed (1), other (1), protein or peptide (1)

Companies

National Cancer Institute (NCI) (1) Timothy Yu (1) Children's Oncology Group (1) David Reardon, MD (1) Exelixis (1) AstraZeneca (1)

Related targets

PRKDC (1) MTOR (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.